SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO) today announced that the American Thoracic Society has released an official clinical practice guideline that provides strong recommendations to measure FENO in patients with asthma. FENO is a point-of-care analytical method for trending and management of airway inflammation which has been pioneered by Aerocrine. Asthma is one of the world’s most widespread diseases and affects more than 300 million people, many of whom are children. Every day, 11 people in the U.S. die from asthma.
